Medically reviewed by Dr. Lauren Nawrocki, DNP, CRNP
Last updated: August 4, 2026
Zepbound generally produces more average weight loss than Contrave in separate clinical trials, but the better choice depends on safety, dosing preference, side effects, and access. Contrave is an oral naltrexone/bupropion tablet that targets appetite and reward pathways. Zepbound is a once-weekly tirzepatide injection that activates GIP and GLP-1 receptors.
The cleanest way to compare Contrave vs Zepbound is to look at 6 decision points: expected weight loss, how each drug works, how each is taken, common side effects, contraindications, and cost or insurance barriers. At Green Relief Health, those factors are reviewed as part of supervised medical weight loss in Baltimore, not as a one-size-fits-all medication choice.
This article is educational and does not diagnose, prescribe, or replace care from a licensed clinician. Prescription weight-loss medication should be selected after a full review of medical history, current prescriptions, pregnancy plans, side-effect risk, and realistic follow-up.
Quick Answer: What Is the Difference Between Contrave and Zepbound?
The main difference is that Zepbound is a once-weekly tirzepatide injection with larger average trial weight loss, while Contrave is a daily naltrexone/bupropion pill with a smaller average effect and different safety restrictions. Zepbound is usually stronger for weight-loss magnitude; Contrave may be discussed when an eligible patient wants an oral option.
- Discuss Zepbound if: larger average weight loss is the priority, weekly injections are acceptable, and there is no personal/family MTC or MEN 2 history.
- Discuss Contrave if: an oral medication is preferred, a more modest average effect fits the goal, and there is no opioid use, seizure history, uncontrolled hypertension, or eating-disorder contraindication.
Difference Summary: Contrave vs Zepbound at a Glance
Contrave vs Zepbound comes down to an oral brain-pathway medication versus an injectable incretin-pathway medication, with Zepbound showing larger average trial weight loss and Contrave offering a non-injection option for eligible patients.
| Comparison point | Contrave | Zepbound |
|---|---|---|
| Active ingredient | Naltrexone HCl 8 mg and bupropion HCl 90 mg per extended-release tablet | Tirzepatide injection |
| Medication type | Opioid antagonist plus aminoketone antidepressant combination | GIP and GLP-1 receptor agonist |
| How it is taken | Oral tablets; maintenance is 2 tablets twice daily | Subcutaneous injection once weekly |
| Expected average trial weight loss | -5.4% in COR-I at 56 weeks versus -1.3% with placebo | -15.0% to -20.9% in Study 1 at 72 weeks versus -3.1% with placebo |
| 5% weight-loss response | 42% in COR-I versus 17% with placebo | 85.1% to 90.9% in Study 1 versus 34.5% with placebo |
| Boxed warning | Suicidal thoughts and behaviors warning related to bupropion | Risk of thyroid C-cell tumors observed in rats; human relevance unknown |
| Main practical concern | Opioid use, seizure risk, blood pressure, psychiatric history, drug interactions | GI side effects, injection use, MTC/MEN 2 contraindication, gallbladder/pancreas/kidney monitoring, access |
The trial numbers are useful but not a head-to-head proof because Contrave and Zepbound were studied in different clinical trials with different durations, populations, dose rules, and lifestyle programs. The FDA labels for Contrave and Zepbound should guide the medical safety discussion.
Difference 1: Zepbound Produces More Average Weight Loss Than Contrave
Zepbound works better for average weight loss in available separate clinical trials, while Contrave produces a smaller average effect that may still be clinically useful for the right patient.
| Evidence point | Contrave | Zepbound |
|---|---|---|
| Main label trial quoted here | COR-I | Study 1 in adults without type 2 diabetes |
| Time point | 56 weeks | 72 weeks |
| Mean body-weight change | -5.4% with Contrave 32 mg/360 mg vs -1.3% with placebo | -15.0% with 5 mg, -19.5% with 10 mg, and -20.9% with 15 mg vs -3.1% with placebo |
| Patients losing at least 5% | 42% with Contrave vs 17% with placebo | 85.1% to 90.9% with Zepbound vs 34.5% with placebo |
| Practical interpretation | More modest average reduction; response must be checked at 12 weeks on maintenance dosing | Larger average reduction; dose escalation and GI tolerance often determine the final usable dose |
For a 200-pound person, 5.4% equals about 10.8 pounds, 15.0% equals 30 pounds, and 20.9% equals 41.8 pounds. Those examples only translate percentages into scale numbers; they do not predict what any one patient will lose.
The 2022 SURMOUNT-1 trial in the New England Journal of Medicine reported large average weight reductions with tirzepatide over 72 weeks, consistent with Zepbound’s label data. Contrave’s label also shows that response is not automatic: if a patient has not lost at least 5% of baseline body weight after 12 weeks at the maintenance dose, the label recommends discontinuing Contrave because meaningful continued loss is unlikely.
Bottom line: If the only question is average weight-loss magnitude, Zepbound has the stronger evidence. If the question is which medication is safer, more practical, or more affordable for a specific person, the answer can change.
Why the numbers are not a direct head-to-head result
Contrave and Zepbound have not been tested against each other in a large randomized head-to-head trial, so the label numbers should be read as separate evidence sets. A head-to-head trial would randomize similar patients at the same time, use the same lifestyle program, define the same primary endpoint, and measure outcomes over the same follow-up period.
The available label data still supports a useful ranking for expected average weight loss, because Zepbound’s placebo-adjusted effect in Study 1 is much larger than Contrave’s placebo-adjusted effect in COR-I. The limitation is that expected average weight loss is only one part of the decision; a patient who cannot safely use Zepbound, cannot access it, or cannot tolerate dose escalation may be better served by another supervised option.
Difference 2: Contrave Works on Appetite and Reward Pathways; Zepbound Works on GIP and GLP-1 Receptors
Contrave and Zepbound both reduce calorie intake, but Contrave acts mainly through brain appetite and reward pathways while Zepbound acts through incretin receptors that affect appetite, digestion, and metabolic signaling.
How Contrave works
Contrave combines naltrexone, an opioid antagonist, with bupropion, an aminoketone antidepressant. The combination is understood to affect appetite and food-reward signaling, though the exact neurochemical effects that lead to weight loss are not fully defined in the label.
This mechanism explains several major safety rules. Because naltrexone blocks opioid receptors, Contrave is not appropriate for people using chronic opioids, methadone, buprenorphine, or acute opioid withdrawal. Because bupropion can affect seizure threshold, mood, blood pressure, and drug interactions, Contrave requires a careful medication and mental-health review.
How Zepbound works
Zepbound contains tirzepatide, which activates GIP and GLP-1 receptors. The medication reduces calorie intake by affecting appetite and slows gastric emptying, especially after starting treatment, which helps explain both weight-loss effects and gastrointestinal side effects.
Zepbound is the tirzepatide brand labeled for chronic weight management. Mounjaro also contains tirzepatide but is labeled for type 2 diabetes; the brand names should not be treated as interchangeable for insurance or prescribing purposes. For a deeper mechanism page, see how Zepbound works for weight loss.
Difference 3: Contrave Is a Daily Pill; Zepbound Is a Weekly Injection
Contrave is taken by mouth every day after a 4-week dose escalation, while Zepbound is injected under the skin once weekly and may be increased no faster than every 4 weeks.
Contrave dosing
Contrave dosing starts with 1 tablet in the morning during week 1, then increases weekly until week 4 and beyond, when the usual maintenance dose is 2 tablets in the morning and 2 tablets in the evening. That maintenance dose equals 32 mg naltrexone and 360 mg bupropion per day.
- Week 1: 1 morning tablet.
- Week 2: 1 morning tablet and 1 evening tablet.
- Week 3: 2 morning tablets and 1 evening tablet.
- Week 4 onward: 2 morning tablets and 2 evening tablets.
Contrave tablets should be swallowed whole and should not be cut, chewed, or crushed. The label says not to take Contrave with a high-fat meal because it significantly increases bupropion and naltrexone exposure. The label also requires a response check after 12 weeks at the maintenance dose.
Zepbound dosing
Zepbound starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly. If more effect is needed and side effects are tolerable, the dose may increase in 2.5 mg steps after at least 4 weeks on the current dose.
The labeled maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg once weekly, and the maximum dose is 15 mg once weekly. Zepbound is injected in the abdomen, thigh, or upper arm, with site rotation. GRH’s Zepbound dose chart lays out the escalation sequence in more detail.
Difference 4: Contrave and Zepbound Have Different Side Effects and Boxed Warnings
Both medications can cause nausea, but Contrave’s major concerns include mood, seizure, opioid, and blood-pressure risks, while Zepbound’s major concerns include gastrointestinal, thyroid, gallbladder, pancreas, dehydration, and injection-related risks.
Common Contrave side effects
The Contrave label lists common adverse reactions at 5% or higher, including nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. The medication also has warnings for increased blood pressure and heart rate, seizure risk, liver injury, angle-closure glaucoma, manic episodes, and hypoglycemia when weight loss occurs in patients using antidiabetic medicines.
Contrave has a boxed warning for suicidal thoughts and behaviors because it contains bupropion. New or worsening depression, agitation, unusual behavior, or suicidal thinking requires urgent clinical attention. Anyone in immediate danger should call 911; in the United States, call or text 988 for the Suicide & Crisis Lifeline.
Common Zepbound side effects
The Zepbound label lists common adverse reactions including nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, allergic reactions, belching, hair loss, and heartburn. GI symptoms are often most relevant during initiation and dose increases.
Zepbound has a boxed warning because tirzepatide caused thyroid C-cell tumors in rats, though human relevance is unknown. The label also warns about severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia when used with insulin or insulin secretagogues, diabetic-retinopathy complications in people with type 2 diabetes, and pulmonary aspiration during anesthesia or deep sedation. See GRH’s focused page on tirzepatide side effects for more detail.
Seek prompt medical care for severe allergic symptoms, a seizure, suicidal thoughts, severe or persistent abdominal pain, repeated vomiting or diarrhea, signs of dehydration, or any rapidly worsening symptom.
Difference 5: Contrave and Zepbound Have Different Contraindications
Contrave and Zepbound have different contraindications, so a person can be a poor candidate for one medication and still need a separate evaluation for the other.
| Medication | Key reasons it may be avoided |
|---|---|
| Contrave | Uncontrolled hypertension, seizure disorder or seizure history, anorexia or bulimia, chronic opioid or opioid-agonist use, acute opioid withdrawal, another bupropion-containing product, abrupt discontinuation of alcohol/benzodiazepines/barbiturates/antiepileptic drugs, MAOI use within 14 days, or allergy to naltrexone, bupropion, or another component. |
| Zepbound | Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or serious hypersensitivity to tirzepatide or another ingredient. Severe GI disease, pancreatitis history, gallbladder disease, kidney risk from dehydration, diabetic retinopathy, oral contraceptive use, and planned anesthesia require focused discussion rather than casual use. |
| Both | Weight-loss medication is not for use during pregnancy. People who are pregnant, trying to conceive, breastfeeding, or using oral contraception should discuss timing and alternatives with a clinician. |
A complete medical weight-loss initial consultation should include prescription medicines, over-the-counter products, supplements, opioid exposure, mental-health history, blood pressure, diabetes medicines, kidney/gallbladder/pancreas history, pregnancy plans, and upcoming procedures.
Difference 6: Contrave May Fit Oral-Option Cases; Zepbound May Fit Larger Weight-Loss Goals
Zepbound may fit better when a larger average weight-loss effect is medically appropriate and injections are acceptable, while Contrave may fit better when an eligible patient wants an oral option and does not have Contrave-specific safety restrictions.
| Decision factor | Contrave may be discussed when… | Zepbound may be discussed when… |
|---|---|---|
| Weight-loss goal | A more modest average effect fits the goal and risk profile. | A larger average effect is needed and tirzepatide is appropriate. |
| Dosing preference | The person strongly prefers pills and can follow twice-daily maintenance dosing. | The person accepts weekly injections and dose escalation. |
| Opioid use | Current opioid therapy generally rules it out. | It does not block opioid receptors, though other risks still apply. |
| Seizure or uncontrolled blood pressure | These generally rule it out. | It may remain possible after evaluation if no Zepbound-specific contraindication applies. |
| MTC or MEN 2 history | It does not have Zepbound’s MTC/MEN 2 contraindication. | Personal/family MTC or MEN 2 rules it out. |
| GI tolerance | Nausea and constipation still matter, but the profile is different. | GI tolerance is a major factor during dose escalation. |
| Access | Coverage or cash-pay programs may be easier for some patients. | Coverage, prior authorization, dose availability, and long-term affordability must be verified. |
The choice should be reassessed during medical weight-loss follow-ups. Response, side effects, blood pressure, dose tolerance, adherence, and affordability can change after treatment starts.
Difference 7: Cost and Insurance Can Favor Either Medication
Zepbound usually has a higher cash-price and more intensive insurance authorization process than Contrave, but the real cost depends on the patient’s plan, pharmacy, deductible, savings eligibility, and dose form.
Before choosing either medication, verify:
- whether the medication is on the plan formulary;
- whether prior authorization or step therapy is required;
- the cost at the likely maintenance dose, not only the starter dose;
- whether a coupon, manufacturer program, or cash-pay option applies;
- how refills are handled if supply changes; and
- what follow-up visits, labs, or monitoring may cost separately.
Cost should not be the only deciding factor. A lower-cost medication that is contraindicated is not a safe bargain, and a higher-cost medication that cannot be continued may not be a practical plan.
Frequently Asked Questions
These focused answers address the main Contrave vs Zepbound decisions patients ask about before a clinician visit.
Is Zepbound stronger than Contrave?
Yes, Zepbound has stronger average weight-loss results in separate clinical trials, with -15.0% to -20.9% mean body-weight change at 72 weeks in Study 1 compared with -5.4% for Contrave at 56 weeks in COR-I. This does not prove every patient will lose more with Zepbound.
Can you take Contrave and Zepbound together?
Do not combine Contrave and Zepbound unless a qualified prescriber specifically decides it is appropriate and monitors the plan. Contrave’s label states that its safety and effectiveness with other weight-loss products have not been established, and Zepbound should not be combined with another tirzepatide product or GLP-1 receptor agonist.
Can you switch from Contrave to Zepbound?
A clinician can sometimes plan a switch from Contrave to Zepbound, but timing depends on side effects, blood pressure, opioid exposure, psychiatric symptoms, medication interactions, insurance approval, and Zepbound-specific contraindications. Do not stop one medication and start the other without medical guidance.
Which is better if I do not want injections?
Contrave is the practical option to discuss if avoiding injections is a top priority and the person has no Contrave contraindications. Zepbound requires weekly injections, so a patient unwilling or unable to inject would need a different plan.
Which is better if I use opioids or have a seizure history?
Zepbound is usually the more relevant medication to discuss if chronic opioid use or seizure history rules out Contrave, but Zepbound still requires its own safety screening. Contrave is contraindicated with chronic opioids, acute opioid withdrawal, seizure disorder, or a history of seizures.
Which is better if I have a family history of medullary thyroid cancer?
Contrave is the medication to discuss instead of Zepbound if the issue is a personal or family history of medullary thyroid carcinoma or MEN 2. Zepbound is contraindicated in those situations.
Discuss Contrave vs Zepbound in Baltimore
Green Relief Health can review whether Contrave, Zepbound, tirzepatide in Baltimore, or another medically appropriate option fits your health history and weight-management goals.
Green Relief Health
Dr. Lauren Nawrocki, DNP, CRNP
7690 Belair Road, Suite 1, Baltimore, MD 21236
Phone: 410-368-0420
Appointments: Book online
An appointment does not guarantee a prescription. Medication choice, dose, monitoring, and follow-up depend on an individualized clinical evaluation.
Brand names belong to their respective owners. This article is for general educational purposes only.
